{"title":"An ITP Patient Taking Eltrombopag Presented with Extreme Thrombocytosis after Orthopedic Surgery.","authors":"Xiuping Xu, Guoxing Ge","doi":"10.7754/Clin.Lab.2024.241218","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Primary immune thrombocytopenia (ITP) is an acquired autoimmune disease characterized by varying degrees of platelet count reduction, with or without skin and mucosal bleeding. Eltrombopag is a thrombopoietin receptor agonist (TPO-RA) that promotes platelet production by specifically binding to the transmembrane domain of thrombopoietin receptor (TPO-R).</p><p><strong>Methods: </strong>Blood routine examination was performed to monitor the changes of platelets in this ITP patient during the treatment of eltrombopag.</p><p><strong>Results: </strong>The ITP patient had an extreme thrombocytosis after open reduction and internal fixation of radial fracture while taking eltrombopag.</p><p><strong>Conclusions: </strong>We believe that this rare case was caused by the co-stimulation of eltrombopag, surgery, inflammation, and artificial bone implant. Therefore, ITP patients taking eltrombopag should monitor platelet changes, especially during infection and surgery, so as to adjust the dose of eltrombopag in time.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"71 6","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical laboratory","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7754/Clin.Lab.2024.241218","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Primary immune thrombocytopenia (ITP) is an acquired autoimmune disease characterized by varying degrees of platelet count reduction, with or without skin and mucosal bleeding. Eltrombopag is a thrombopoietin receptor agonist (TPO-RA) that promotes platelet production by specifically binding to the transmembrane domain of thrombopoietin receptor (TPO-R).
Methods: Blood routine examination was performed to monitor the changes of platelets in this ITP patient during the treatment of eltrombopag.
Results: The ITP patient had an extreme thrombocytosis after open reduction and internal fixation of radial fracture while taking eltrombopag.
Conclusions: We believe that this rare case was caused by the co-stimulation of eltrombopag, surgery, inflammation, and artificial bone implant. Therefore, ITP patients taking eltrombopag should monitor platelet changes, especially during infection and surgery, so as to adjust the dose of eltrombopag in time.
期刊介绍：
Clinical Laboratory is an international fully peer-reviewed journal covering all aspects of laboratory medicine and transfusion medicine. In addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies. The journal publishes original articles, review articles, posters, short reports, case studies and letters to the editor dealing with 1) the scientific background, implementation and diagnostic significance of laboratory methods employed in hospitals, blood banks and physicians'' offices and with 2) scientific, administrative and clinical aspects of transfusion medicine and 3) in addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
